The primary one I've been sold on is types of crystal growth is just better up there. But due to the excess expense, the only thing that fits the bill is experimental edge case pharmaceuticals that have massive price tags that insurance mostly covers.

If the automation improves far beyond what we currently have available, maybe this means microchip manufacturing in the future, but we aren't at all there yet from the fab side of the equation.